Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascelia Pharma AB ( (SE:ACE) ) has shared an update.
Ascelia Pharma AB announced its intention to conduct a directed share issue to raise approximately SEK 30 million from institutional investors. This strategic move aims to diversify the company’s investor base and strengthen its financial position, extending its cash runway into Q4 2026. The funds will support ongoing partnering activities and prepare for the anticipated FDA response to its new drug application. The decision to deviate from shareholders’ preferential rights is driven by the need for a more efficient, cost-effective capital raise, mitigating risks associated with a traditional rights issue.
More about Ascelia Pharma AB
Ascelia Pharma AB is a pharmaceutical company focused on developing and commercializing novel drugs for unmet medical needs. The company operates primarily in the pharmaceutical industry, targeting international markets with its innovative healthcare solutions.
YTD Price Performance: 33.73%
Average Trading Volume: 1,055,913
Technical Sentiment Signal: Sell
Current Market Cap: SEK453.1M
Learn more about ACE stock on TipRanks’ Stock Analysis page.